HENMT1

Summary

HENMT1 (HEN methyltransferase 1, HGNC:26400) is a protein-coding gene on chromosome 1p13.3, encoding Small RNA 2’-O-methyltransferase (Q5T8I9). Methyltransferase that adds a 2’-O-methyl group at the 3’-end of piRNAs, a class of 24 to 30 nucleotide RNAs that are generated by a Dicer-independent mechanism and are primarily derived from transposons and other repeated sequence elements.

Enables small RNA 2’-O-methyltransferase activity. Involved in RNA methylation. Predicted to be located in P granule. Predicted to be active in cytoplasm and nucleus.

Source: NCBI Gene 113802 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 75 total — 2 pathogenic
• MANE Select transcript: NM_001102592

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26400
Approved symbol	HENMT1
Name	HEN methyltransferase 1
Location	1p13.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ30525, HEN1
Ensembl gene	ENSG00000162639
Ensembl biotype	protein_coding
OMIM	612178
Entrez	113802

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 11 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000370031, ENST00000370032, ENST00000483729, ENST00000493676, ENST00000651461, ENST00000868362, ENST00000868363, ENST00000868364, ENST00000868365, ENST00000912747, ENST00000912748, ENST00000968606, ENST00000968607

RefSeq mRNA: 2 — MANE Select: NM_001102592 NM_001102592, NM_144584

CCDS: CCDS787

Canonical transcript exons

ENST00000651461 — 8 exons

Exon	Start	End
ENSE00003559555	108657451	108657579
ENSE00003573529	108650211	108650388
ENSE00003628053	108651030	108651209
ENSE00003672776	108654716	108654850
ENSE00003848308	108660963	108661093
ENSE00003892510	108655586	108655698
ENSE00003892786	108648295	108648991
ENSE00003893960	108659864	108659962

Expression profiles

Bgee: expression breadth ubiquitous, 214 present calls, max score 99.13.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.1676 / max 129.0103, expressed in 1248 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
13651	3.8429	901
13653	1.4688	526
13652	1.3372	670
13650	0.5188	294

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	99.13	gold quality
secondary oocyte	CL:0000655	98.75	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	98.38	gold quality
right testis	UBERON:0004534	96.13	gold quality
left testis	UBERON:0004533	95.91	gold quality
testis	UBERON:0000473	95.32	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	94.09	gold quality
granulocyte	CL:0000094	89.88	gold quality
adult organism	UBERON:0007023	88.01	gold quality
cortical plate	UBERON:0005343	86.55	gold quality
pons	UBERON:0000988	86.42	gold quality
leukocyte	CL:0000738	85.68	gold quality
monocyte	CL:0000576	85.31	gold quality
thymus	UBERON:0002370	85.29	gold quality
ileal mucosa	UBERON:0000331	85.14	gold quality
prefrontal cortex	UBERON:0000451	84.67	gold quality
lateral nuclear group of thalamus	UBERON:0002736	84.33	silver quality
blood	UBERON:0000178	83.85	gold quality
bone marrow	UBERON:0002371	83.71	gold quality
hypothalamus	UBERON:0001898	83.40	gold quality
substantia nigra pars compacta	UBERON:0001965	83.02	gold quality
substantia nigra pars reticulata	UBERON:0001966	82.92	gold quality
lymph node	UBERON:0000029	82.61	gold quality
Brodmann (1909) area 9	UBERON:0013540	82.59	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	82.42	gold quality
Brodmann (1909) area 46	UBERON:0006483	82.03	gold quality
frontal cortex	UBERON:0001870	81.95	gold quality
nucleus accumbens	UBERON:0001882	81.87	gold quality
anterior cingulate cortex	UBERON:0009835	81.84	gold quality
rectum	UBERON:0001052	81.77	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-134144	yes	29.61
E-ANND-3	yes	5.93
E-MTAB-7249	no	203.50

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

20 targeting HENMT1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-183-3P	99.41	69.41	1598
HSA-MIR-6507-3P	99.35	67.32	1059
HSA-MIR-3190-5P	98.87	64.89	1345
HSA-MIR-4725-5P	98.67	65.42	628
HSA-MIR-504-5P	98.67	65.40	631
HSA-MIR-6516-5P	98.42	70.19	1551
HSA-MIR-3159	97.94	66.79	1098
HSA-MIR-526B-5P	97.41	67.99	1074

Literature-anchored findings (GeneRIF, showing 4)

• HENMT1 and PIWI proteins are expressed in a germ-cell-specific manner and required for transposon control. (PMID:28676534)
• The proposed PEC bioassay exhibited high selectivity and low detection limit of 3.36ng/mL for HENMT1 activity assay. Furthermore, the inhibition research indicated that chlorpyrifos could inhibit the HENMT1 activity with the IC50 value of 48.32nM. (PMID:29277012)
• methylation substrates in mouse spermatogonial stem cells and the substrate-recognition mechanism of mammalian Hen1 (PMID:29703750)
• Screening of potential key genes in esophageal cancer based on RBP and expression verification of HENMT1. (PMID:38065897)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	henmt1	ENSDARG00000018871
mus_musculus	Henmt1	ENSMUSG00000045662
rattus_norvegicus	Henmt1	ENSRNOG00000042814
drosophila_melanogaster	Hen1	FBGN0033686
caenorhabditis_elegans		WBGENE00015349

Protein

Protein identifiers

Small RNA 2’-O-methyltransferase — Q5T8I9 (reviewed: Q5T8I9)

Alternative names: HEN1 methyltransferase homolog 1

All UniProt accessions (2): Q5T8I9, A0A0A0MRN1

UniProt curated annotations — full annotation on UniProt →

Function. Methyltransferase that adds a 2’-O-methyl group at the 3’-end of piRNAs, a class of 24 to 30 nucleotide RNAs that are generated by a Dicer-independent mechanism and are primarily derived from transposons and other repeated sequence elements. This probably protects the 3’-end of piRNAs from uridylation activity and subsequent degradation. Stabilization of piRNAs is essential for gametogenesis.

Subcellular location. Cytoplasm.

Cofactor. Binds 1 Mg(2+) ion per subunit.

Similarity. Belongs to the methyltransferase superfamily. HEN1 family.

RefSeq proteins (2): NP_001096062, NP_653185 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026610	Hen1	Family
IPR029063	SAM-dependent_MTases_sf	Homologous_superfamily

Pfam: PF13489

Catalyzed reactions (Rhea), 1 shown:

• small RNA 3’-end nucleotide + S-adenosyl-L-methionine = small RNA 3’-end 2’-O-methylnucleotide + S-adenosyl-L-homocysteine + H(+) (RHEA:37887)

UniProt features (40 total): helix 12, binding site 10, strand 9, sequence variant 3, sequence conflict 2, chain 1, region of interest 1, compositionally biased region 1, turn 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
5WY0	X-RAY DIFFRACTION	2
4XCX	X-RAY DIFFRACTION	2.84

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5T8I9-F1	85.67	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (10): 135; 136; 181; 36; 55; 78; 83; 115; 131; 132

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-5601884	PIWI-interacting RNA (piRNA) biogenesis

MSigDB gene sets: 79 (showing top): GOBP_RNA_METHYLATION, GOBP_RNA_MODIFICATION, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, GOBP_PIRNA_PROCESSING, GOBP_METHYLATION, LIU_BREAST_CANCER, GOCC_RIBONUCLEOPROTEIN_GRANULE, GOCC_POLE_PLASM, GOMF_RNA_METHYLTRANSFERASE_ACTIVITY, GOMF_O_METHYLTRANSFERASE_ACTIVITY, GOMF_TRANSFERASE_ACTIVITY_TRANSFERRING_ONE_CARBON_GROUPS, MEISSNER_NPC_HCP_WITH_H3_UNMETHYLATED, MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED, MARTENS_TRETINOIN_RESPONSE_DN, GOBP_SIRNA_PROCESSING

GO Biological Process (5): RNA methylation (GO:0001510), siRNA processing (GO:0030422), piRNA processing (GO:0034587), regulatory ncRNA-mediated gene silencing (GO:0031047), methylation (GO:0032259)

GO Molecular Function (8): RNA binding (GO:0003723), O-methyltransferase activity (GO:0008171), RNA methyltransferase activity (GO:0008173), metal ion binding (GO:0046872), small RNA 2’-O-ribose methyltransferase activity (GO:0090486), protein binding (GO:0005515), methyltransferase activity (GO:0008168), transferase activity (GO:0016740)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), P granule (GO:0043186)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Gene Silencing by RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulatory ncRNA processing	2
methyltransferase activity	2
RNA modification	1
macromolecule methylation	1
negative regulation of gene expression	1
metabolic process	1
nucleic acid binding	1
catalytic activity, acting on RNA	1
cation binding	1
RNA 2’-O-methyltransferase activity	1
binding	1
transferase activity, transferring one-carbon groups	1
catalytic activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoplasmic ribonucleoprotein granule	1
germ plasm	1

Protein interactions and networks

STRING

666 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HENMT1	PIWIL1	Q96J94	825
HENMT1	PIWIL4	Q7Z3Z4	813
HENMT1	TARBP2	Q15633	787
HENMT1	DICER1	Q9UPY3	764
HENMT1	PLD6	Q8N2A8	732
HENMT1	AGO2	Q9UKV8	726
HENMT1	PNLDC1	Q8NA58	686
HENMT1	TDRKH	Q9Y2W6	683
HENMT1	AGO1	Q9UL18	682
HENMT1	TDRD9	Q8NDG6	668
HENMT1	AGO3	Q9H9G7	649
HENMT1	AGO4	Q9HCK5	648
HENMT1	PIWIL2	Q8TC59	632
HENMT1	ZFP36	P26651	613
HENMT1	DROSHA	Q9NRR4	609

IntAct

15 interactions, top by confidence:

A	B	Type	Score
TRAF2	HENMT1	psi-mi:“MI:0915”(physical association)	0.560
HENMT1	TRAF2	psi-mi:“MI:0915”(physical association)	0.560
HENMT1	CCDC74B	psi-mi:“MI:0915”(physical association)	0.560
INCA1	HENMT1	psi-mi:“MI:0915”(physical association)	0.560
HENMT1	tax	psi-mi:“MI:0915”(physical association)	0.560
tax	HENMT1	psi-mi:“MI:0915”(physical association)	0.560
HENMT1	SNX2	psi-mi:“MI:0914”(association)	0.530
HENMT1	RAD51C	psi-mi:“MI:0914”(association)	0.350
HENMT1	INCA1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (18): HENMT1 (Two-hybrid), PECR (Affinity Capture-MS), MTHFD2L (Affinity Capture-MS), SNX6 (Affinity Capture-MS), KIF3A (Affinity Capture-MS), SNX2 (Affinity Capture-MS), SBF1 (Affinity Capture-MS), TXLNA (Affinity Capture-MS), RAD51C (Affinity Capture-MS), HENMT1 (Two-hybrid), INCA1 (Two-hybrid), SNX6 (Affinity Capture-MS), KIF3A (Affinity Capture-MS), MTHFD2L (Affinity Capture-MS), SBF1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4IMY7, A0A0R4IY06, A0JPF9, A2AP18, A5PJN5, C0IN03, D2KX21, E1BVR9, E9PYK3, F1ND48, O00534, O75038, O94952, O95237, P0C1Q3, P53817, Q1LWG4, Q1LZ50, Q32PY6, Q4R3W5, Q4R6L3, Q5M7X9, Q5R5S1, Q5RJG7, Q5S6T3, Q5T8I9, Q6DC39, Q75WE7, Q7Z5M8, Q7ZU92, Q8BYI6, Q8C0L6, Q8CAE2, Q8CAS9, Q8K3R3, Q8NHH9, Q8SPR7, Q8VDH1, Q90678, Q93V51

Diamond homologs: C0IN03, E1BVR9, H9JDT2, P34283, Q230X8, Q32PY6, Q4R3W5, Q568P9, Q5T8I9, Q7K175, Q8CAE2, Q9C5Q8, Q9UST9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

75 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	56
Likely benign	7
Benign	3

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1328955	NM_001102592.2(HENMT1):c.226G>A (p.Gly76Arg)	Pathogenic
1328956	NM_001102592.2(HENMT1):c.456C>G (p.Tyr152Ter)	Pathogenic

SpliceAI

1140 predictions. Top by Δscore:

Variant	Effect	Δscore
1:108650207:TCAC:T	donor_loss	1.0000
1:108650208:CAC:C	donor_loss	1.0000
1:108650209:A:AC	donor_gain	1.0000
1:108650209:ACAG:A	donor_gain	1.0000
1:108650210:C:CC	donor_gain	1.0000
1:108650210:C:CG	donor_loss	1.0000
1:108650210:CA:C	donor_gain	1.0000
1:108650210:CAG:C	donor_gain	1.0000
1:108650210:CAGC:C	donor_gain	1.0000
1:108650210:CAGCT:C	donor_gain	1.0000
1:108650265:T:A	donor_gain	1.0000
1:108650384:AAGCC:A	acceptor_gain	1.0000
1:108650385:AGCC:A	acceptor_gain	1.0000
1:108650386:GCC:G	acceptor_gain	1.0000
1:108650387:CC:C	acceptor_gain	1.0000
1:108650387:CCC:C	acceptor_gain	1.0000
1:108650387:CCCTG:C	acceptor_loss	1.0000
1:108650388:CC:C	acceptor_gain	1.0000
1:108650389:C:CC	acceptor_gain	1.0000
1:108650389:C:T	acceptor_gain	1.0000
1:108650390:T:A	acceptor_loss	1.0000
1:108650396:C:T	acceptor_gain	1.0000
1:108651205:CTATT:C	acceptor_gain	1.0000
1:108654714:A:AC	donor_gain	1.0000
1:108654715:C:CC	donor_gain	1.0000
1:108654715:CA:C	donor_gain	1.0000
1:108654715:CAA:C	donor_gain	1.0000
1:108654715:CAAT:C	donor_gain	1.0000
1:108654715:CAATT:C	donor_gain	1.0000
1:108657575:CTGCA:C	acceptor_gain	1.0000

AlphaMissense

2562 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:108651125:G:C	S161R	0.998
1:108651125:G:T	S161R	0.998
1:108651127:T:G	S161R	0.998
1:108651107:G:C	F167L	0.996
1:108651107:G:T	F167L	0.996
1:108651109:A:G	F167L	0.996
1:108651059:A:C	F183L	0.995
1:108651059:A:T	F183L	0.995
1:108651061:A:G	F183L	0.995
1:108651203:T:A	E135D	0.995
1:108651203:T:G	E135D	0.995
1:108651055:A:G	W185R	0.994
1:108651055:A:T	W185R	0.994
1:108654719:T:A	E132V	0.994
1:108651204:T:A	E135V	0.993
1:108650298:A:C	C223W	0.992
1:108651056:C:A	E184D	0.992
1:108651056:C:G	E184D	0.992
1:108651077:T:A	R177S	0.992
1:108651077:T:G	R177S	0.992
1:108650281:A:G	F229S	0.990
1:108651116:G:C	N164K	0.990
1:108651116:G:T	N164K	0.990
1:108651200:A:C	H136Q	0.990
1:108651200:A:T	H136Q	0.990
1:108657520:A:C	F27L	0.990
1:108657520:A:T	F27L	0.990
1:108657522:A:G	F27L	0.990
1:108651067:G:C	H181D	0.989
1:108651078:C:G	R177T	0.989

dbSNP variants (sampled 300 via entrez): RS1000149852 (1:108662199 C>G,T), RS1000233564 (1:108657756 G>GT), RS1000237633 (1:108656864 T>C,G), RS1000663176 (1:108661670 C>T), RS1000820354 (1:108661883 G>A,T), RS1000870603 (1:108650926 G>C), RS1001018769 (1:108661118 A>G), RS1001186517 (1:108655204 T>C), RS1001258485 (1:108655429 A>G), RS1001535002 (1:108661272 G>C), RS1002133237 (1:108660182 T>A,C,G), RS1002178824 (1:108658925 G>C), RS1002187304 (1:108653704 T>C), RS1002264491 (1:108653973 T>C), RS1002303705 (1:108653074 C>T)

Disease associations

OMIM: gene MIM:612178 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): azoospermia (MONDO:0100459), male infertility (MONDO:0005372)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D053713	Azoospermia	C12.100.500.430.380; C12.100.750.700.380; C12.200.294.430.380
D007248	Infertility, Male	C12.100.500.430; C12.100.750.700; C12.200.294.430

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression	6
methylmercuric chloride	increases expression	2
entinostat	increases expression, affects cotreatment	2
GSK-J4	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
beta-lapachone	increases expression	1
butyraldehyde	increases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
avobenzone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	affects binding, decreases reaction	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cisplatin	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diazinon	increases methylation	1
Hydralazine	affects cotreatment, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Thimerosal	increases expression	1
Tretinoin	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1TI	Abcam HeLa HENMT1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

150 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02307994	PHASE4	UNKNOWN	Clinical Research on Effectiveness and Safety of Treatment of Severe Oligospermia or Azoospermia With uFSH
NCT02202382	PHASE4	COMPLETED	Effects of Korean Red Ginseng on Male Infertility
NCT02204826	PHASE4	COMPLETED	Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study
NCT03802864	PHASE4	COMPLETED	Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine
NCT06100432	PHASE4	ACTIVE_NOT_RECRUITING	Effect of Eurycoma Longifolia (DLBS5055) and Multivitamins (Vitamin C+Vitamin E+ β-carotene) for Infertile Males
NCT07523022	PHASE4	ENROLLING_BY_INVITATION	Comparison of the Effect of Gonadotropin and Clomiphene Citrate Treatment on Sperm Parameters and the Outcome of Assisted Reproductive Procedures in Subfertile Men Based on the APHRODITE Groups
NCT02275169	PHASE3	UNKNOWN	FSH Treatment for Non-obstructive Azoospermic Patients
NCT00975117	PHASE3	COMPLETED	Spermotrend in the Treatment of Male Infertility
NCT01407432	PHASE3	COMPLETED	Impact of Folates in the Care of the Male Infertility
NCT01895816	PHASE3	COMPLETED	Herbal Tonic Fertile Supplement(ZO2C5)
NCT02605070	PHASE3	TERMINATED	Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia
NCT07402759	PHASE3	ACTIVE_NOT_RECRUITING	Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men
NCT02544191	PHASE2	UNKNOWN	GnRHa Combined With hCG and hMG for Treatment of Patients With Non-obstructive Azoospermia
NCT03762967	PHASE2	UNKNOWN	Autologous Adipose-Derived Adult Stromal Vascular Cell Administration for Male Patients With Infertility
NCT01880086	PHASE2	COMPLETED	Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration
NCT02061384	PHASE2	COMPLETED	RA-2 13-cis Retinoic Acid (Isotretinoin)
NCT02421887	PHASE2	COMPLETED	Males, Antioxidants, and Infertility Trial
NCT05200663	PHASE2	UNKNOWN	Efficacy Comparison of Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Male With Idiopathic Infertility
NCT05290558	PHASE2	ACTIVE_NOT_RECRUITING	The Therapeutic Effects of Bu Shen Yi Jing Pill on Semen Quality in Sub Fertile Males: a Randomized Controlled Trial
NCT06091969	PHASE2	NOT_YET_RECRUITING	Supplementation for Male Subfertility
NCT01595308	PHASE1	COMPLETED	A Pilot Study to Evaluate the Effect of Pomegranate Juice on Semen Parameters in Healthy Male Volunteers
NCT02122211	PHASE1	COMPLETED	Choline Dehydrogenase and Sperm Function: Effects of Betaine
NCT02575924	PHASE1	UNKNOWN	Influence of Culture Media on Clinical Outcomes in Poor Responders or Severe Male Infertility
NCT02041910	PHASE1/PHASE2	UNKNOWN	Testicular Injection of Autologous Stem Cells for Treatment of Patients With Azoospermia
NCT00282477	Not specified	UNKNOWN	Trial to Evaluate Erectile Function, Fertility and Sperm Count in Male Cyclists Compared to Age Matched Controls
NCT00484081	Not specified	COMPLETED	Microdissection Testicular Sperm Extraction (MicroTESE) and IVF-ICSI Outcome in Non-Obstructive Azoospermia (NOA)
NCT00548977	Not specified	COMPLETED	Genetic Studies Spermatogenic Failure
NCT01375062	Not specified	COMPLETED	Obtaining Undifferentiated Cells From Testis Biopsy
NCT01509482	Not specified	COMPLETED	Insulin Resistance in Idiopathic Oligospermia and Azoospermia
NCT02008799	Not specified	UNKNOWN	Intra Testicular Artery Injection of Bone Marrow Stem Cell in Management of Azoospermia
NCT02339272	Not specified	COMPLETED	Study of Synapsis and Recombination in Male Meiosis and the Implications in Infertility
NCT02414295	Not specified	COMPLETED	Sperm Production in Kleinfelter Syndrome Patients After Mesenchymal Stem Cell Injection
NCT02418832	Not specified	RECRUITING	Testis Needle Aspiration of Sperm in Men With Azoospermia
NCT02617173	Not specified	UNKNOWN	The Effect of Low Electrical Current on Testicular Spermatocyte Count
NCT02773498	Not specified	TERMINATED	Comparison of Medical Results of Testicular Sperm Extraction by Conventional Surgery and Microsurgical Track
NCT03497728	Not specified	TERMINATED	Detection of Microdeletions in the Azoospermia Factor (AZF) Regions in Infertile Male Patients
NCT04675164	Not specified	COMPLETED	Laser Assisted Sperm Selection of Viable Immotile Testicular Sperm in Azoospermic Infertile Men
NCT05479474	Not specified	RECRUITING	Platelet Rich Plasma Testis Treatment for Infertile Men
NCT05628987	Not specified	RECRUITING	The Association of Gut Microbiota and Spermatogenic Dysfunction
NCT05866484	Not specified	COMPLETED	Testicular Sperm Aspiration (TESA) vs. Microfluidic Sperm Separation (MSS)